DOCSLIB.ORG

Medical Genetics and Genomics Milestones

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Medical Genetics and Genomics Milestones Medical Genetics and Genomics Milestones The Accreditation Council for Graduate Medical Education Second Revision: August 2019 First Revision: July 2013 Medical Genetics and Genomics Milestones The Milestones are designed only for use in evaluation of residents in the context of their participation in ACGME-accredited residency or fellowship programs. The Milestones provide a framework for the assessment of the development of the resident in key dimensions of the elements of physician competency in a specialty or subspecialty. They neither represent the entirety of the dimensions of the six domains of physician competency, nor are they designed to be relevant in any other context. ©2019 Accreditation Council for Graduate Medical Education (ACGME) All rights reserved except the copyright owners grant third parties the right to use the Medical Genetics and Genomics Milestones on a non-exclusive basis for educational purposes. ii Medical Genetics and Genomics Milestones Work Group Miriam Blitzer, PhD Kate Hatlak, MSEd Michelle Cichon, MS Susan Klugman, MD Kristina Cusmano-Ozog, MD Melissa Lah, MD Katrina Dipple, MD, PhD Nathaniel Robin, MD Laura Edgar, EdD, CAE Brian Shayota, MD, MPH Paul Hillman, MD, PhD Joan Stoler, MD Fuki Hisama, MD V. Reid Sutton, MD The ACGME would like to thank the following organizations for their continued support in the development of the Milestones: American Board of Medical Genetics and Genomics Association of Professors of Human and Medical Genetics ACGME Review Committee for Medical Genetics and Genomics ©2019 Accreditation Council for Graduate Medical Education (ACGME) All rights reserved except the copyright owners grant third parties the right to use the Medical Genetics and Genomics Milestones on a non-exclusive basis for educational purposes. iii Understanding Milestone Levels and Reporting This document presents Milestones designed for programs to use in semi-annual review of resident performance and reporting to the ACGME. Milestones are knowledge, skills, attitudes, and other attributes for each of the ACGME competencies organized in a developmental framework. The narrative descriptions are targets for resident performance throughout their training. For each reporting period, the Clinical Competency Committee will review the completed evaluations to select the milestone levels that best describe each resident’s current performance, abilities and attributes for each subcompetency. Milestones are arranged into levels. Tracking from Level 1 to Level 5 is synonymous with moving from novice to expert resident in the specialty. These levels do not correspond with post-graduate year of education. Depending on previous experience, a junior resident may achieve higher levels early in training just as a senior resident may be at a lower level later in training. There is no predetermined timing for a resident to attain any particular level. A resident may also regress in their milestones. This may happen for many reasons, such as over scoring in the previous meeting, disjointed experience in a particular procedure, or significant act by the resident. Selection of a level implies that the resident substantially demonstrates the milestones in that level, as well as those in lower levels (see the diagram on page v). ©2019 Accreditation Council for Graduate Medical Education (ACGME) All rights reserved except the copyright owners grant third parties the right to use the Medical Genetics and Genomics Milestones on a non-exclusive basis for educational purposes. iv Additional Notes For residents who have insufficient data/evaluations to assess, please choose “not yet assessable.” Level 4 is designed as a graduation goal and does not represent a graduation requirement. Making decisions about readiness for graduation and unsupervised practice is the purview of the residency program director. Furthermore, Milestones 2.0 include revisions and changes that preclude using Milestones as a sole assessment in high stakes decisions (i.e. determination of eligibility for certification or credentialing). Level 5 is designed to represent an expert resident whose achievements in a subcompetency are greater than the expectation. Milestones are primarily designed for formative, developmental purposes to support continuous quality improvement for individual learners, training programs, and the specialty. ACGME and its partners will continue to evaluate and perform research on the Milestones 2.0 sets to assess their impact and value. Examples are provided for some milestones within this document. Please note that the examples are not the required element or outcome; they are provided as a way to share the intent of the element. Some milestone descriptions include statements about performing independently. These activities must occur in conformity to the ACGME supervision guidelines, as well as to institutional and program policies. For example, a resident who performs a procedure independently must, at a minimum, be supervised through oversight. A Supplemental Guide is also available. This Guide provides the intent of each subcompetency, examples for each level, assessment methods or tools, and other resources that are available. This Guide, like examples contained within the Milestones, was designed to assist the program director and Clinical Competency Committee and is not meant to demonstrate any required element or outcome. Additional resources are available on the Milestones section of the ACGME website. Follow the links under “What We Do” at www.acgme.org. ©2019 Accreditation Council for Graduate Medical Education (ACGME) All rights reserved except the copyright owners grant third parties the right to use the Medical Genetics and Genomics Milestones on a non-exclusive basis for educational purposes. v The diagram below presents an example set of milestones for one sub-competency in the same format as the ACGME Report Worksheet. For each reporting period, a resident’s performance on the milestones for each sub-competency will be indicated by selecting the level of milestones that best describes that resident’s performance in relation to those milestones. Selecting a response box in the Selecting a response box on the line in middle of a level implies that between levels indicates that milestones milestones in that level and in lower in lower levels have been substantially levels have been substantially demonstrated as well as some demonstrated. milestones in the higher level(s). ©2019 Accreditation Council for Graduate Medical Education (ACGME) All rights reserved except the copyright owners grant third parties the right to use the Medical Genetics and Genomics Milestones on a non-exclusive basis for educational purposes. vi Version 2 Medical Genetics and Genomics Milestones, ACGME Report Worksheet Patient Care 1: History and Physical Examination Level 1 Level 2 Level 3 Level 4 Level 5 Takes a general medical Takes a basic genetics- Takes a genetics-focused Takes a comprehensive Makes a nationally and family history focused history and history with some genetic history with recognized contribution completes a basic pertinent positive and pertinent positive and by describing a new pedigree negative findings; negative findings; genetic disorder or completes an accurate integrates the history expanding the phenotype pedigree with other data to of a known syndrome or disorder develop a differential diagnosis Completes a general Completes a basic Completes a genetics- Identifies and accurately physical examination genetics-focused physical focused physical describes phenotypic examination; identifies examination; identifies features and/or normal and abnormal and accurately describes anomalies using phenotypic features common phenotypic standardized and/or anomalies features and/or nomenclature; anomalies; recognizes recognizes complex common syndromes or syndromes or disorders disorders Comments: Not Yet Completed Level 1 Not Yet Assessable ©2019 Accreditation Council for Graduate Medical Education (ACGME) All rights reserved except the copyright owners grant third parties the right to use the Medical Genetics and Genomics Milestones on a non-exclusive basis for educational purposes. 1 Version 2 Medical Genetics and Genomics Milestones, ACGME Report Worksheet Patient Care 2: Selecting Tests, Interpreting Results, and Management of Genetic Conditions Level 1 Level 2 Level 3 Level 4 Level 5 Identifies the variety of Identifies basic testing Identifies strengths and Selects and prioritizes testing modalities for options for common limitations of testing testing options across a genetic conditions genetic disorders methodologies in order to broad spectrum of select first tier tests complex disorders and inheritance patterns/ Contributes to the mechanisms knowledge base for the refinement of ambiguous Identifies the Identifies resources to Uses resources to Uses resources to test results components of the facilitate interpretation of interpret diagnostic test interpret ambiguous test genetics test result positive, negative, and results in the context of results in the context of uncertain test results the phenotype the phenotype Recognizes the Identifies resources and Implements treatment Implements treatment Creates evidence-based availability of intervention guidelines for treatment and/or surveillance plans and/or surveillance guidelines for for some genetic and management of for common genetic plans for complex management conditions common genetic conditions genetic conditions conditions Comments: Not Yet Completed
Load more

Recommended publications
  • AMP Molecular Genetic Pathology Recommended Review Books
    ASSOCIATION FOR MOLECULAR PATHOLOGY Education. Innovation & Improved Patient Care. Advocacy. 6120 Executive Blvd. Suite 700, Rockville, MD 20852 Tel: 301-634-7939 | Fax: 301-634-7995 | [email protected] | www.amp.org AMP Molecular Genetic Pathology : RECOMMENDED REVIEW BOOKS Updated: March, 2021 The following books are suggested for those preparing for the Molecular Genetic Pathology board exam administered by the American Board of Medical Genetics and the American Board of Pathology. This list represents the recommendations of the MGP Review Course faculty and the AMP Training and Education Committee; endorsement by the ABMG or the ABP is not implied. GENERAL MOLECULAR PATHOLOGY Thompson & Thompson Genetics in Medicine, 8th edition Nussbaum RL et al., eds. Elsevier, 2015 Molecular Pathology: The Molecular Basis of Human Diseases 2nd edition Coleman WB and Tsongalis GJ, eds. Elsevier, 2018 Diagnostic Molecular Pathology: A Guide to Applied Molecular Testing Coleman WB and Tsongalis GJ, eds. Elsevier, 2016 Molecular Basis of Human Cancer, 2nd edition Coleman WB and Tsongalis GJ, eds. Elsevier, 2017 Molecular Diagnostics: Fundamentals, Methods, and Clinical Applications 3rd edition Buckingham L. ASCP, 2021 Genomic Medicine: A Practical Guide Tafe LJ and Arcila ME, eds. Springer, 2020 CYTOGENETICS Gardner and Sutherland’s Chromosome Abnormalities and Genetic Counseling, 5th edition McKinlay Gardner RJ, Amor DJ. Oxford University Press, 2018 The Principles of Clinical Cytogenetics, 3rd edition Gersen SL and Keagle MB, eds. Human Press, 2013 Human Chromosomes, 4th edition Miller OJ and Therman E, eds. Springer Press, 2000 Vance GH, Khan WA. Utility of Fluorescence In Situ Hybridization in Clinical and Research Applications. Advances in Molecular Pathology 2020; 3:65-75.
    [Show full text]
  • Leave Policy for Residents and Fellows.Pdf
    Leave Policy for Residents and Fellows The following policy outlines indications and training modifications to accommodate leave during accredited training for certification in all of the ABMGG specialties. Candidates for certification are required to successfully complete training in one of the following programs: ACGME-accredited Programs: 24 months (2 years) • Medical Genetics and Genomics Residency • Clinical Biochemical Genetics Postdoctoral Fellowship • Laboratory Genetics and Genomics Postdoctoral Fellowship Approved Combined Residency Programs: 48 months (4 years) • Medical Genetics and Genomics/Internal Medicine • Medical Genetics and Genomics/Pediatrics • Medical Genetics and Genomics/Maternal Fetal Medicine • Medical Genetics and Genomics/Reproductive Endocrinology and Infertility Subspecialty Fellowship Programs: 12 months (1 year) • Medical Biochemical Genetics • Molecular Genetic Pathology (cosponsored with American Board of Pathology) General Leave Policy: All candidates are allotted 4 weeks leave per year, which may be accrued or averaged through the duration of training for any indication. All candidates must take at least one week off per year as designated vacation time. Leave time cannot be forfeited to shorten training duration. Parental, Caregiver, and Medical Leave Policy: This policy refers to leave for the following indications: parental leave (the birth and care of a newborn including adopted and foster children for either partner), caregiver leave (care for an immediate (first degree) family member or partner with a serious health condition), or medical leave for significant personal medical needs. For Parental, Caregiver, and Medical leave, the ABMGG will allow up to 6 weeks leave during an academic year to occur once during the training program. For trainees who take indicated leave, they must still take at least one additional week for vacation during the same training year.
    [Show full text]
  • Department of Molecular Biology and Immunology
    Genetics Student Handbook 2020-2021 The information provided in this document serves to supplement the requirements of the Graduate School of Biomedical Sciences detailed in the UNTHSC Catalog with requirements specific to the Genetics discipline. Genetics Discipline (8/6/20) 1 Table of Contents Page Description of the Genetics Discipline ............................................ 3 Graduate Faculty and Their Research ............................................. 5 Requirements ................................................................................... 9 Required Courses ....................................................................... 9 Journal Club and Seminar Courses ............................................ 9 Elective Courses ......................................................................... 9 Sample Degree Plans ..................................................................... 11 Advancement to Candidacy ........................................................... 14 Genetics Discipline (8/6/20) 2 1. Description of the Genetics Discipline John V. Planz, Ph.D., Graduate Advisor Center for BioHealth, Rm 360 Phone: 817-735-2397 E-mail: [email protected] Program website: www.unthsc.edu/graduate-school-of-biomedical-sciences/genetics/ Graduate Faculty: Allen; Barber; Budowle; Cihlar; Coble; Ge; Phillips; Planz; Woerner Genetics is a broad interdisciplinary field that unites biochemistry, microbial and cellular biology, molecular processes, biotechnology, computational biology, biogeography and human disease
    [Show full text]
  • Importance of Medical Genetics Research in Medicine
    cs an eti d D n N e A G f R Journal of Genetics and DNA o e l s a e a n Sboui S, Tabbabi A, J Genet DNA Res 2018, 2:1 r r c u h o J Research Short Communication Open Access Importance of Medical Genetics Research in Medicine Sajida Sboui1 and Ahmed Tabbabi2* 1Faculty of Medicine of Monastir, Monastir University, Monastir, Tunisia 2Department of Hygiene and Environmental Protection, Ministry of Public Health, Tunis, Tunisia *Corresponding author: Ahmed Tabbabi, Department of Hygiene and Environmental Protection, Ministry of Public Health, Tunis, Tunisia, Tel: +216 71 577 115; +216 71 577 302; E-mail: [email protected] Received date: February 09, 2018, Accepted date: February 20, 2018, Published date: February 27, 2018 Copyright: © 2018 Sboui S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Keywords: Chromosome; Genes; Cleft lip; Transforming growth In medical genetics, the work diagnosis includes molecular analyzes factors (DNA, proteins and chromosomes) and clinical manisfestations of conditions, including malformations birth. If monogenic diseases are Short Communication rare, those caused by the gene/environment interaction are common and include many diseases. Prevention in medical genetics involves for About millions of families are affected by hereditary diseases around common pathologies the identification of subjects with high risk, with the world. Statistics analysis showed that about 5% of all pregnancies the intention of preventing the disease (e.g.
    [Show full text]
  • An Updated Primer
    The new england journal of medicine review article Genomic Medicine W. Gregory Feero, M.D., Ph.D., and Alan E. Guttmacher, M.D., Editors Genomic Medicine — An Updated Primer W. Gregory Feero, M.D., Ph.D., Alan E. Guttmacher, M.D., and Francis S. Collins, M.D., Ph.D. Cathy, a 40-year-old mother of three, arrives in your office for her annual physical. From the National Human Genome Re- She has purchased a commercial genomewide scan (see the Glossary), which she be- search Institute (W.G.F.), the Eunice Ken- nedy Shriver National Institute of Child lieves measures the clinically meaningful risk that common diseases will develop, H e al t h an d Human D e ve l o p m e n t ( A . E .G .), and has completed her family history online using My Family Health Portrait (www and the Office of the Director (F.S.C.), .familyhistory.hhs.gov), a tool developed for this purpose by the U.S. Surgeon Gen- National Institutes of Health, Bethesda, MD; and the Maine Dartmouth Family eral. Her genomewide scan suggests a slightly elevated risk of breast cancer, but Medicine Residency Program, Augusta, you correctly recognize that this information is of unproven value in routine clinical ME (W.G.F.). Address reprint requests to care. On importing Cathy’s family-history file, your office’s electronic health record Dr. Feero at the National Human Ge- nome Research Institute, National Insti- system alerts you to the fact that Cathy is of Ashkenazi Jewish heritage and has sev- tutes of Health, Bldg.
    [Show full text]
  • Genetic Testing for BRCA Mutations: a POLICY PAPER
    Genetic testing for BRCA mutations: A POLICY PAPER 2019 This report was initiated and funded by Pfizer. Pfizer has provided funding to The Health Policy Partnership (HPP) for research, drafting and coordination. The report was written by Kirsten Budig, Jody Tate and Suzanne Wait from HPP under the guidance of a group of expert contributors. The experts contributed through telephone interviews and written comments, and were not financially compensated for their time. The following expert contributors were consulted and provided feedback during the development of this European-level report and the country profiles, for which we are hugely grateful. European-level report • Karen Benn, Deputy CEO/ Head of Public Affairs, Europa Donna • Antonella Cardone, Director, European Cancer Patient Coalition • Lydia Makaroff, former Director, European Cancer Patient Coalition; current Chief Executive Officer, Fight Bladder Cancer • Elżbieta Senkus-Konefka, Associate Professor at the Department of Oncology and Radiotherapy, Medical University of Gdańsk, Poland France country profile • Pascal Pujol, President, BRCA-France; Professor of Medical Genetics, Centre Hospitalier Universitaire de Montpellier • Dominique Stoppa-Lyonnet, Director of the Genetics Department, Institut Curie; Professor of Genetics, University Paris-Descartes Germany country profile • Rita Schmutzler, Director, Centre for Breast and Ovarian Cancer, Cologne • Evelin Schröck, Director, Institute for Clinical Genetics at the TU Dresden Ireland country profile • Liz Yeates, CEO, Marie
    [Show full text]
  • Genomic-Based Personalized Medicine (Reference Committee E)
    REPORT 4 OF THE COUNCIL ON SCIENCE AND PUBLIC HEALTH (A-10) Genomic-based Personalized Medicine (Reference Committee E) EXECUTIVE SUMMARY Objectives. The term “personalized medicine” (PM) refers to health care that is informed by each person’s unique clinical, genetic, and environmental information. Clinical integration of PM technologies is enabling health care providers to more easily detect individual differences in susceptibility to particular diseases or in response to specific treatments, then tailor preventive and therapeutic interventions to maximize benefit and minimize harm. This report will review current status of genomic-based PM and challenges to implementing it, and will briefly summarize the activities of key federal agencies, professional organizations, coalitions, and health systems that are working to further the integration of genomic-based technologies into routine care. Data Sources. Literature searches were conducted in the PubMed database for English-language articles published between 2005 and 2010 using the search terms “personalized medicine” and “personalized medicine AND clinic.” To capture reports that may not have been indexed on PubMed, a Google search was also conducted using the search term “personalized medicine.” Additional articles were identified by review of the literature citations in articles and identified from the PubMed and Google searches. Results. Genetic testing has been a routine part of clinical care for a number of years in screening and diagnosis. Recently, a number of genomic-based applications have advanced beyond these screening and diagnostic techniques and are “personalizing” the delivery of care by enabling risk prediction, therapy, and prognosis that is tailored to individual patients. Yet there are challenges to the clinical implementation of PM, such as the lack of genetics knowledge among health care providers, slow generation of clinical validity and utility evidence, a fragmentary oversight and regulatory system, and lack of insurance coverage of PM technologies.
    [Show full text]
  • Simulation Based Virtual Learning Environment in Medical Genetics
    Makransky et al. BMC Medical Education (2016) 16:98 DOI 10.1186/s12909-016-0620-6 RESEARCH ARTICLE Open Access Simulation based virtual learning environment in medical genetics counseling: an example of bridging the gap between theory and practice in medical education Guido Makransky1*, Mads T. Bonde2, Julie S. G. Wulff1, Jakob Wandall3, Michelle Hood4, Peter A. Creed4, Iben Bache5,6, Asli Silahtaroglu5 and Anne Nørremølle5 Abstract Background: Simulation based learning environments are designed to improve the quality of medical education by allowing students to interact with patients, diagnostic laboratory procedures, and patient data in a virtual environment. However, few studies have evaluated whether simulation based learning environments increase students’ knowledge, intrinsic motivation, and self-efficacy, and help them generalize from laboratory analyses to clinical practice and health decision-making. Methods: An entire class of 300 University of Copenhagen first-year undergraduate students, most with a major in medicine, received a 2-h training session in a simulation based learning environment. The main outcomes were pre- to post- changes in knowledge, intrinsic motivation, and self-efficacy, together with post-intervention evaluation of the effect of the simulation on student understanding of everyday clinical practice were demonstrated. Results: Knowledge (Cohen’s d = 0.73), intrinsic motivation (d =0.24),andself-efficacy(d = 0.46) significantly increased from the pre- to post-test. Low knowledge students showed the greatest increases in knowledge (d =3.35)andself- efficacy (d = 0.61), but a non-significant increase in intrinsic motivation (d = 0.22). The medium and high knowledge students showed significant increases in knowledge (d = 1.45 and 0.36, respectively), motivation (d = 0.22 and 0.31), and self-efficacy (d = 0.36 and 0.52, respectively).
    [Show full text]
  • Precision and Personalized Medicine: How Genomic Approach Improves the Management of Cardiovascular and Neurodegenerative Disease
    G C A T T A C G G C A T genes Review Precision and Personalized Medicine: How Genomic Approach Improves the Management of Cardiovascular and Neurodegenerative Disease Oriana Strianese 1,2, Francesca Rizzo 2 , Michele Ciccarelli 3 , Gennaro Galasso 3, Ylenia D’Agostino 2, Annamaria Salvati 2 , Carmine Del Giudice 1, Paola Tesorio 4 and Maria Rosaria Rusciano 1,3,* 1 Clinical Research and Innovation, Clinica Montevergine S.p.A., 83013 Mercogliano, Italy; [email protected] (O.S.); [email protected] (C.D.G.) 2 Laboratory of Molecular Medicine and Genomics, Department of Medicine, Surgery and Dentistry, Scuola Medica Salernitana, University of Salerno, 84084 Baronissi, Italy; [email protected] (F.R.); [email protected] (Y.D.); [email protected] (A.S.) 3 Department of Medicine, Surgery and Dentistry, Scuola Medica Salernitana, University of Salerno, 84084 Baronissi, Italy; [email protected] (M.C.); [email protected] (G.G.) 4 Unit of Cardiology, Clinica Montevergine S.p.A., 83013 Mercogliano, Italy; [email protected] * Correspondence: [email protected] Received: 18 June 2020; Accepted: 2 July 2020; Published: 6 July 2020 Abstract: Life expectancy has gradually grown over the last century. This has deeply affected healthcare costs, since the growth of an aging population is correlated to the increasing burden of chronic diseases. This represents the interesting challenge of how to manage patients with chronic diseases in order to improve health care budgets. Effective primary prevention could represent a promising route. To this end, precision, together with personalized medicine, are useful instruments in order to investigate pathological processes before the appearance of clinical symptoms and to guide physicians to choose a targeted therapy to manage the patient.
    [Show full text]
  • Clinical Appropriateness Guidelines
    Clinical Appropriateness Guidelines Whole Exome and Whole Genome Sequencing EFFECTIVE MARCH 31, 2019 Appropriate.Safe.Affordable © 2019 AIM Specialty Health 2067-0319b Table of Contents Scope ................................................................................................................................................................ 3 Genetic Counseling Requirement ................................................................................................................... 3 Appropriate Use Criteria .................................................................................................................................. 3 Whole Exome Sequencing ................................................................................................................... 3 Whole Exome Reanalysis ..................................................................................................................... 4 Whole Genome Sequencing ................................................................................................................ 5 CPT Codes......................................................................................................................................................... 5 Background ...................................................................................................................................................... 5 Rationale for Genetic Counseling for WES ......................................................................................... 6 Professional
    [Show full text]
  • Medical Genetics: End of the Beginning Or Beginning of the End? Reed E
    ACMGpresidentialadd ress Medical genetics: end of the beginning or beginning of the end? Reed E. Pyeritz, MD, PhD Interest in the human aspects of genetics is at an all-time high. Rarely we must be aware of perception as well as reality. We need to wony that does a week pass when the national media fail to report that a gene has some people think the field of genetics wiU end in 2005, or sooner, if been associated with, or a chromosomal region linked to a human phe- the US, international, or private Human Genome Projects continue at notype. The American Medical Association (AMA) recently sponsored their current pace. a course expressly to educate primary care providers about genetics issues relevant to their practices. The Vice-President of the United States was The future of education in medical genetics the featured speaker at an event sponsored by the Genome Action Coali- Traditionally, medical geneticists, trained as PhD-certified laboratory tion and was given the JamesWatson Award. Vice-President Gore chose directors, MS-certified genetic counselors, MD-certified clinical geneti- the occasion to announce that the Administration would sponsor legis- cists, or a combination thereof, have functioned in education, clinical lation to prohibit discrimination in the workplace based on genetic infor- service, and research. One can certainly argue persuasively that the era mation. President Clinton, in his State of the Union Address, said: of the "triple threatn has passed, but even the professional who is pro- Think about this-the entire store of human knowledge ductive in one or two of these areas is encountering problems.
    [Show full text]
  • Diagnostic Interpretation of Genetic Studies in Patients with Primary
    AAAAI Work Group Report Diagnostic interpretation of genetic studies in patients with primary immunodeficiency diseases: A working group report of the Primary Immunodeficiency Diseases Committee of the American Academy of Allergy, Asthma & Immunology Ivan K. Chinn, MD,a,b Alice Y. Chan, MD, PhD,c Karin Chen, MD,d Janet Chou, MD,e,f Morna J. Dorsey, MD, MMSc,c Joud Hajjar, MD, MS,a,b Artemio M. Jongco III, MPH, MD, PhD,g,h,i Michael D. Keller, MD,j Lisa J. Kobrynski, MD, MPH,k Attila Kumanovics, MD,l Monica G. Lawrence, MD,m Jennifer W. Leiding, MD,n,o,p Patricia L. Lugar, MD,q Jordan S. Orange, MD, PhD,r,s Kiran Patel, MD,k Craig D. Platt, MD, PhD,e,f Jennifer M. Puck, MD,c Nikita Raje, MD,t,u Neil Romberg, MD,v,w Maria A. Slack, MD,x,y Kathleen E. Sullivan, MD, PhD,v,w Teresa K. Tarrant, MD,z Troy R. Torgerson, MD, PhD,aa,bb and Jolan E. Walter, MD, PhDn,o,cc Houston, Tex; San Francisco, Calif; Salt Lake City, Utah; Boston, Mass; Great Neck and Rochester, NY; Washington, DC; Atlanta, Ga; Rochester, Minn; Charlottesville, Va; St Petersburg, Fla; Durham, NC; Kansas City, Mo; Philadelphia, Pa; and Seattle, Wash AAAAI Position Statements,Work Group Reports, and Systematic Reviews are not to be considered to reflect current AAAAI standards or policy after five years from the date of publication. The statement below is not to be construed as dictating an exclusive course of action nor is it intended to replace the medical judgment of healthcare professionals.
    [Show full text]